U.S. Generic Injectables Pharmaceutical Contract Manufacturing Market Is Projected To Grow Robustly
U.S. Generic Injectables Pharmaceutical Contract Manufacturing Market Summary The U.S. generic injectables pharmaceutical contract manufacturing market size was estimated at USD 3.0 billion in 2024 and is projected to grow at a CAGR of 10.8% from 2025 to 2030. Growth in the market can be attributed to the rising frequency of patent expirations for blockbuster drugs, streamlined regulatory pathways and low cost of generics, and the increasing number of market players entering generic injectables CDMOs. Currently, one of the major factors fueling the market growth is the rising frequency at which injectable medications are losing their patent protection. For instance, in July 2023, the patent for Sanofi's highly successful medication Mozobil expired, leading to the introduction of generic versions of Plerixafor. Moreover, growing outsourcing by pharmaceutical companies, growing drug shortage, rising prevalence of cancer and age-related disorders, and increasing investm...